Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-11-2008 | Original Article

Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia

Authors: Anne-Mette Lebech, Ulrik Sloth Kristoffersen, Niels Wiinberg, Kristian Kofoed, Ove Andersen, Birger Hesse, Claus Leth Petersen, Jan Gerstoft, Andreas Kjær

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2008

Abstract

Background

The mechanisms underlying increased cardiovascular risk in HIV patients in antiretroviral therapy (ART) are not known. Our aim was to study the endothelial function of the coronary arteries by cardiac perfusion positron emission tomography (PET), in HIV patients with normal or high cholesterol levels. Flow mediated dilation (FMD) of the brachial artery and circulating endothelial markers were also assessed.

Methods and results

HIV patients in ART with total cholesterol ≤ 5.5 mmol/L (215 mg/dL; n = 13) or total cholesterol ≥ 6.5 mmol/L (254 mg/dL; n = 12) and healthy controls (n = 14) were included. ¹³NH₃ perfusion PET, FMD, and measurement of plasma levels of E-Selectin, ICAM-1, VCAM-1, tPAI-1, and hs-CRP were performed. Baseline myocardial perfusion and the coronary flow reserve measured by PET (3.2 ± 0.3, 3.2 ± 0.3 and 3.0 ± 0.3; ns) was similar in HIV patients with normal or high total cholesterol and controls. FMD did not differ between the groups and was 4.6 ± 1.1%, 5.1 ± 1.2%, and 4.6 ± 0.8%, respectively. Increased levels of plasma E-Selectin, ICAM-1, tPAI-1, and hs-CRP were found in HIV patients when compared to controls (p < 0.05). E-Selectin and ICAM-1 levels were higher in HIV patients receiving protease inhibitors (PI) compared to those not receiving PI (p < 0.05). None of the measured endothelial biomarkers differed between the normal and high cholesterol HIV groups.

Conclusions

In ART-treated HIV patients with a low overall cardiovascular risk, no sign of endothelial dysfunction was found not even in hypercholesterolemic patients. Also, the increased level of plasma endothelial markers found in HIV patients was not related to hypercholesterolemia.

Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853–60.PubMedCrossRef

Friis-Moller N, Sabin CA, Weber R, Monforte AD, El Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993–2003.PubMedCrossRef

Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, Monforte AD, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. Aids 2003;17:1179–93.PubMedCrossRef

Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747–8.PubMedCrossRef

Mary-Krause M, Cotteb L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. Aids 2003;17:2479–86.PubMedCrossRef

Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007;44:1625–31.PubMedCrossRef

Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723–35.PubMedCrossRef

Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 1990;16:349–56.PubMedCrossRef

Zeiher AM, Schachinger V, Weitzel SH, Wollschlager H, Just H. Intracoronary thrombus formation causes focal vasoconstriction of epicardial arteries in patients with coronary artery disease. Circulation 1991;83:1519–25.PubMed

10.

Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995;74:247–53.PubMedCrossRef

11.

Beanlands RS, Muzik O, Melon P, Sutor R, Sawada S, Muller D, et al. Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. Determination of extent of altered vascular reactivity. J Am Coll Cardiol 1995;26:1465–75.PubMedCrossRef

12.

Demer LL, Gould KL, Goldstein RA, Kirkeeide RL, Mullani NA, Smalling RW, et al. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative arteriography in 193 patients. Circulation 1989;79:825–35.PubMed

13.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 2001;285:2486–97.CrossRef

14.

Kjaer A, Meyer C, Nielsen FS, Parving HH, Hesse B. Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. J Nucl Med 2003;44:19–23.PubMed

15.

Kjaer A, Meyer C, Wachtell K, Olsen MH, Ibsen H, Opie L, et al. Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy. Am J Cardiol 2005;96:1692–8.PubMedCrossRef

16.

Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257–65.PubMedCrossRef

17.

Grunfeld C, Kotler DP, Shigenaga JK, Doerrler W, Tierney A, Wang J, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154–62.PubMed

18.

Hirsch HH, Battegay M. HIV-infection, HAART and hyperlipidaemia. Dtsch Med Wochenschr 2003;128:1051–4.PubMedCrossRef

19.

Lichtenstein K, Armon C, Buchacz K, Moorman AC, Wood KC, Brooks J. Analysis of cardiovascular risk factors in the HIV outpatient study cohort. Presented at the 13th Conference on Retroviruses and Opportunistic Infections.Denver, CO; February 5–8, 2006. 2006.

20.

Blanco JJ, Garcia IS, Cerezo JG, de Rivera JM, Anaya PM, Raya PG, et al. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother 2006;58:133–9.PubMedCrossRef

21.

Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM—An International Journal of Medicine 2003;96:825–32.PubMed

22.

Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven DE, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006;42:1325–32.PubMedCrossRef

23.

Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257–62.PubMed

24.

Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004;147:E18.PubMed

25.

van Wijk JP, de Koning EJ, Cabezas MC, Joven J, op’t RJ, Rabelink TJ, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006;47:1117–23.PubMedCrossRef

26.

Mangili A, Gerrior J, Tang AM, O’Leary DH, Polak JK, Schaefer EJ, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis 2006;43:1482–9.PubMedCrossRef

27.

de Larranaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis 2003;14:15–8.PubMedCrossRef

28.

Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang XL, et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 2006;47:1188–95.PubMedCrossRef

29.

Nagamachi S, Czernin J, Kim AS, Sun KT, Bottcher M, Phelps ME, et al. Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET. J Nucl Med 1996;37:1626–31.PubMed

30.

Bottcher M, Czernin J, Sun K, Phelps ME, Schelbert HR. Effect of beta 1 adrenergic receptor blockade on myocardial blood flow and vasodilatory capacity. J Nucl Med 1997;38:442–6.PubMed

31.

van den Heuvel AF, Blanksma PK, Siebelink HM, van Wijk LM, Boomsma F, Vaalburg W, et al. Impairment of myocardial blood flow reserve in patients with asymptomatic left ventricular dysfunction: effects of ACE-inhibition with perindopril. Int J Cardiovasc Imaging 2001;17:353–9.PubMedCrossRef

32.

Catzin-Kuhlmann A, Orea-Tejeda A, Castillo-Martinez L, Colin-Ramirez E, Asz D, Aguirre VH, et al. Human immunodeficiency virus-infected subjects have no altered myocardial perfusion. Int J Cardiol 2007;122:90–2.PubMedCrossRef

33.

Thiebaut F, Aurillac-Lavignolle V, Bonnet F, Ibrahim N, Cipriano C, Neau D, et al. Change in atherosclerosis progression in HIV infected patients: ANRS Aquitaine cohort, 1999–2004. Aids 2005;19:729–31.PubMedCrossRef

34.

Flammer A, Vo T, Ledergerber B, Gämperli A, Lahn A, Grube C, et al. Effect of Atazanavir (ATV) versus other protease inhibitor (PI)-containing antiretroviral combination therapy on endothelial function in HIV-infected persons:randomized controlled trial. Presented at the 8th International Congress on Drug Therapy in HIV infection. Glascow, UK; November 12–16, 2006. 2006.

35.

El Sadr W, Neaton J. Late Breaker - Episodic CD4-Guided Use of Antiretroviral Therapy is Inferior to Continuous Therapy: Results of the SMART Study. Presented at the 13th Conference on Retroviruses and Opportunistic Infections.Denver, CO; February 5–8, 2006. 2006.

36.

Grubb JR, Dejam A, Voell J, Blackwelder WC, Sklar PA, Kovacs JA, et al. Lopinavir–ritonavir: effects on endothelial cell function in healthy subjects. J Infect Dis 2006;193:1516–9.PubMedCrossRef

37.

Shankar SS, Dube MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005;150:933.PubMedCrossRef

38.

Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–43.PubMedCrossRef

39.

Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481–85.PubMedCrossRef

40.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–65.PubMedCrossRef

Title: Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia
Authors: Anne-Mette Lebech
Ulrik Sloth Kristoffersen
Niels Wiinberg
Kristian Kofoed
Ove Andersen
Birger Hesse
Claus Leth Petersen
Jan Gerstoft
Andreas Kjær
Publication date: 01-11-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0846-6

At a glance: The STEP trials

Springer Medicine

Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia

Abstract

Background

Methods and results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods and results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2008

No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving 131I radiometabolic therapy, as evaluated by micronucleus assay and microarray analysis

99mTc-apcitide scintigraphy in patients with clinically suspected deep venous thrombosis and pulmonary embolism

FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis

Prognostic value of sympathetic innervation and cardiac asynchrony in dilated cardiomyopathy

Respiratory motion handling is mandatory to accomplish the high-resolution PET destiny

Comprehensive evaluation of occupational radiation exposure to intraoperative and perioperative personnel from 18F-FDG radioguided surgical procedures